

Supplemental table 1. Oligonucleotides used in this study

Oligonucleotide	Sequence (5' to 3')	Purpose	Reference
KAN-2 FP-1	ACCTACAACAAAGCTCTCATCAACC	Sequence analysis of all strains	This study
KAN-2 RP-1	GCAATGTAACATCAGAGATTTTGAG	Sequence analysis of all strains	This study
M13 R	CGACGTTGTAACGACGGCCAGT	Sequence analysis strain 330	This study
2d-RP3	TGGAAGGTACCTGGATGGC	Sequence analysis strain 330	This study
3c-RP3	TGGTCATCGCGCTCGGTG	Sequence analysis strain 330	This study
3c-RP4	TCACCACCAGCGCACCGC	Sequence analysis strain 330	This study
6b-FP3	ACCGGGGTGGTCAGCTCG	Sequence analysis strain 330	This study
6b-FP4	TGCGTTACCGGGTGACCG	Sequence analysis strain 330	This study
4b-FP3	GACGACTGGTCGTGCCCG	Sequence analysis strain 1510	This study
4b-FP4	CCGTCACCGTTCTCGAGG	Sequence analysis strain 1510	This study
4c-RP3	GATGCTCCAGTGCCTGGTG	Sequence analysis strain 1510	This study
4c-RP4	TCCTGTCTCGCCACAGGG	Sequence analysis strain 1510	This study
1d-RP3	GGCGAATTCGGCCAGTGC	Sequence analysis strain 1608	This study
1d-RP4	GTCGGGCTGTTGTTCCC	Sequence analysis strain 1608	This study
16S rRNA 400F	ACGAAGCTGAGTGACGGTA	Quantification of 16S rRNA	1
16S rRNA 500RV	ACTCAAGTCTGCCCGTATCG	Quantification of 16S rRNA	1
RT-tlsA-200F	CCGACGGACAAGTCCAATGC	Quantification of <i>tlsA</i>	This study
RT-tlsA-200RV	CGACACCGTGTGCTCGATCG	Quantification of <i>tlsA</i>	This study
RT-alkB-200F	GCATGGCTGATGACCCTCG	Quantification of <i>alkB</i>	This study
RT-alkB-200RV	GCACAGGCGATCACTGTTCC	Quantification of <i>alkB</i>	This study
RT-fda-200F	CGAGAAGGGCAAGTACCTGC	Quantification of <i>fda</i>	This study
RT-fda-160RV	CGTGGAAGACGAAGTCGAACG	Quantification of <i>fda</i>	This study
tlsA-F	CCCAAGCTTGAGCAACTGCATCGACACCG	Complementation of <i>tlsA</i>	This study
tlsA-Rv	CCCAAGCTTGGGTTCCCGGTAGATCGAACG	Complementation of <i>tlsA</i>	This study
alkB-F	CGGGATCCGGTCAACGACGCGATATCTTAC	Complementation of <i>alkB</i>	This study
alkB-Rv	CCCAAGCTTGCAGGTTTTCGACACAGCC	Complementation of <i>alkB</i>	This study
fda-F	CGGGATCCGATGTTGCCGAGGAAGTAGC	Complementation of <i>fda</i>	This study
fda-Rv	CCCAAGCTTGTCTGAAACCGGTGTCAGCTCGC	Complementation of <i>fda</i>	This study
D191-A_FM	GTGTGCGCGTGAGCGATCGCATGGAAGAG	Point mutation of D191A	This study
D191-A_RM	CTCTTCCATGCGATCGCTCACGCGCACAC	Point mutation of D191A	This study
H192-A_FM	GTCGGTGTGCGCGGCATCGATCGC	Point mutation of H192A	This study
H192-A_RM	GCGATCGATGCCGCGCACACCGAC	Point mutation of H192A	This study
D196-A_FM	CGACTGCATGGCGGTGTGCGCG	Point mutation of D196A	This study
D196-A_RM	CGCGCACACCGCCATGCAGTCG	Point mutation of D196A	This study
exp-fda-F	GGAATTCATATGCCAATTGCGACTCCCAGGTCTACG	Expression of <i>Fda</i> and <i>Fda-His</i>	This study
exp-fda-Rv	CGCAAGCTTGCTCGCGGACACCGAGCGTCC	Expression of <i>Fda</i>	This study
exp-fda-Rv-His	CGCAAGCTTTCAGCTCGCGGACACCGAGCGTCC	Expression of <i>Fda-His</i>	This study
pro-alkB-rubB-F	GCCTCTAGACACCTGCTCGACGGACAGG	Construction of overexpression plasmid	This study
pro-alkB-RV	GGCAAGCTTCTCCAGTGTCTCGTGACGC	Construction of overexpression plasmid	This study
x-tlsA-F	CCGAAGCTTCTCACTAGTTCAGGAGCC	Overexpression of <i>tlsA</i>	This study
x-tlsA1-RV	CCGAAGCTTGTGTCATCCCGCCGATCCG	Overexpression of <i>tlsA</i>	This study
x-fda-F	CCGAAGCTTCTGCTGGTGATCACAGCGC	Overexpression of <i>fda</i>	This study
x-fda-RV	CCGAAGCTTCTGAAACCGGTGTCAGCTCG	Overexpression of <i>fda</i>	This study

Supplemental table 1. Inaba *et al.*

References of supplemental materials

1. **Miranda-CasoLuengo, R., P. S. Duffy, E. P. O'Connell, B. J. Graham, M. W.**

Mangan, J. F. Prescott, and W. G. Meijer. 2005. The iron-regulated *iupABC*

operon is required for saprophytic growth of the intracellular pathogen

Rhodococcus equi at low iron concentrations. J. Bacteriol. **187**:3438-3444.